Superworth

Maxcyte revenue MXCT

Sales by quarter and over the last twelve months, from 2020.

Last 12 months, to Jun 30, 2026
$31.1M
Latest quarter, Q2 FY26
$7.3M
−15% on a year earlier
Fiscal year 2025
$33M
−15% on the year before

Maxcyte's revenue was $31.1M over the twelve months to Jun 30, 2026, down 13% on a year earlier.

In its latest quarter, Q2 FY26, it was $7.3M, down 15% on the same quarter a year before.

Over the five fiscal years to FY2025 it grew 5% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$33M−15%
FY2024$38.6M−6%
FY2023$41.3M−7%
FY2022$44.3M+31%
FY2021$33.9M+30%
FY2020$26.2Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q2 FY26$7.3M−15%$31.1M
Q1 FY26$9.7M−7%$32.3M
Q4 FY25$7.3M−16%$33M
Q3 FY25$6.8M−16%$34.4M
Q2 FY25$8.5M−18%$35.8M
Q1 FY25$10.4M−8%$37.7M
Q4 FY24$8.7M−45%$38.6M
Q3 FY24$8.2M+2%$45.6M
Q2 FY24$10.4M+15%$45.4M
Q1 FY24$11.3M+32%$44.1M
Q4 FY23$15.7M+26%$41.3M
Q3 FY23$8M−25%$38M

Against its peers

Companies in Healthcare nearest Maxcyte's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
MXCTMaxcyte$31.1M−13% a year
PDEXPro DEX$77.5M+16% a year
PLXProtalix BioTherapeutics$80.6M+30% a year
NATRNatures Sunshine Products$492M+7% a year
KEQUKewaunee Scientific$277.2M+5% a year
ELMDElectromed$73.8M+15% a year
ICCCImmucell$30.7M+8% a year
UTMDUtah Medical Products$36.1M−7% a year
INFUInfuSystem$143.3M+2% a year
LFVNLifevantage$182.6M−20% a year
SPROSpero Therapeutics$47M−3% a year
Peer median$79.1M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Maxcyte

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.